| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTGDR |
| Uniprot No | Q13258 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-359aa |
| 氨基酸序列 | MKSPFYRCQNTTSVEKGNSAVMGGVLFSTGLLGNLLALGLLARSGLGWCSRRPLRPLPSVFYMLVCGLTVTDLLGKCLLSPVVLAAYAQNRSLRVLAPALDNSLCQAFAFFMSFFGLSSTLQLLAMALECWLSLGHPFFYRRHITLRLGALVAPVVSAFSLAFCALPFMGFGKFVQYCPGTWCFIQMVHEEGSLSVLGYSVLYSSLMALLVLATVLCNLGAMRNLYAMHRRLQRHPRSCTRDCAEPRADGREASPQPLEELDHLLLLALMTVLFTMCSLPVIYRAYYGAFKDVKEKNRTSEEAEDLRALRFLSVISIVDPWIFIIFRSPVFRIFFHKIFIRPLRYRSRCSNSTNMESSL |
| 预测分子量 | 40.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTGDR(前列腺素D2受体)重组蛋白的参考文献示例，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*Molecular Cloning and Characterization of the Human Prostanoid DP Receptor*
**作者**：Hirai, H. et al.
**摘要**：该研究首次克隆并表达了人源PTGDR(DP1受体)的cDNA，通过体外重组蛋白表达系统(如CHO细胞)验证其与前列腺素D2(PGD2)的高亲和力结合，并分析了受体在不同组织中的分布及其信号传导机制。
2. **文献名称**：*Crystal Structure of the Human Prostaglandin D2 Receptor DP1 in Complex with an Antagonist*
**作者**：Jazayeri, A. et al.
**摘要**：通过X射线晶体学解析了重组人源PTGDR(DP1)的分子结构，揭示了受体与拮抗剂的结合模式，为基于结构的药物设计提供了关键信息，并阐明了其配体选择性机制。
3. **文献名称**：*Functional Characterization of Recombinant PTGDR2 (CRTH2) in Eosinophil Chemotaxis*
**作者**：Hirai, H. et al.
**摘要**：研究利用重组表达的PTGDR2(DP2/CRTH2)蛋白，证明其在嗜酸性粒细胞趋化中的作用，揭示了PGD2通过CRTH2介导过敏反应的分子机制，并筛选了特异性拮抗剂。
4. **文献名称**：*High-Level Expression and Purification of Human PTGDR in Baculovirus-Insect Cell System*
**作者**：Wang, Y. et al.
**摘要**：报道了一种基于杆状病毒-昆虫细胞系统的高效表达和纯化重组PTGDR的方法，优化了蛋白产量和稳定性，为后续受体功能研究和药物筛选提供了可靠的重组蛋白来源。
---
**说明**：以上文献为示例性质，实际检索时需通过PubMed或Google Scholar核对具体信息。重点关注关键词“PTGDR recombinant expression”“DP1/DP2 receptor structure/function”等。
**Background of PTGDR Recombinant Protein**
The prostaglandin D2 receptor (PTGDR), also known as the DP receptor, is a G protein-coupled receptor (GPCR) that binds prostaglandin D2 (PGD2), a lipid mediator involved in inflammatory and allergic responses. PGD2 is primarily released by mast cells, dendritic cells, and T-helper 2 (Th2) cells, playing a critical role in mediating bronchoconstriction, vasodilation, and immune cell recruitment in conditions such as asthma, allergic rhinitis, and atopic dermatitis. PTGDR exists in two subtypes: DP1 (PTGDR) and DP2 (CRTH2), which differ in signaling pathways and physiological effects. DP1 activation typically leads to anti-inflammatory responses, while DP2 promotes pro-inflammatory activities.
Recombinant PTGDR proteins are engineered versions of these receptors, produced using biotechnological methods such as expression in mammalian, insect, or bacterial cell systems. These proteins retain the functional and structural properties of native receptors, enabling researchers to study ligand-receptor interactions, signaling mechanisms, and receptor modulation in controlled environments. The production of PTGDR recombinant proteins often involves tagging (e.g., His-tag, FLAG-tag) to facilitate purification and detection.
PTGDR recombinant proteins are vital tools in drug discovery, particularly for developing antagonists or agonists targeting allergic and inflammatory diseases. They are used in high-throughput screening assays, structural biology studies (e.g., X-ray crystallography), and functional analyses to identify therapeutic candidates. Additionally, these proteins aid in elucidating the pathophysiological roles of PGD2 signaling and validating receptor-specific drug effects. By providing a consistent and scalable source of functional receptors, recombinant PTGDR proteins accelerate research into novel treatments for immune-mediated disorders, bridging gaps between molecular understanding and clinical applications.
×
